S

Sanofi

Global pharma company; vaccines and R&D

Vaccine Manufacturing Manager Production Influenza Bulk Drug Substance Upstream

Full-TimeDeadline 10/31/26
$90k - $130k
Senior
Bachelor's, Associate's
Swiftwater, PA, USA
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A Bachelor's degree and at least 5 years of experience in Quality, Production, manufacturing operations, or a related field; alternatively, an Associate's degree and at least 7 years of such experience; or a High School degree and at least 10 years of such experience.
  • Experience managing, supervising, or leading teams.
  • Experience in viral manufacturing and/or bacterial manufacturing.
  • Ability to work on cross-functional project teams.
  • Demonstrated ability to meet or exceed timelines and deliverables.
  • Knowledge of continuous improvement techniques and problem-solving and analytical skills.
  • Ability to negotiate and influence.
  • Ability to lift up to 50 pounds, stand an average of 8 hours per shift, and gown and gain entry to manufacturing areas.
  • Ability to work a twelve-hour rotating shift and every other weekend, including holidays as scheduled.
  • May need to flex into another platform within MTech and/or another Manufacturing & Supply department, and work weekends, holidays, or off-shift hours based on business needs.
  • May work in an aseptic processing area.
Responsibilities
  • Manage multiple priorities independently or as part of a team to meet key deadlines.
  • Communicate issues and progress across all levels of the organization.
  • Resolve Quality Assurance shop-floor observations promptly to maintain product quality.
  • Perform monthly Health, Safety, and Environment audits, complete HSE investigations, and support HSE Corrective and Preventive Actions.
  • Perform GEMBA walks to ensure adherence to quality and compliance in facilities.
  • Support deviation closures to ensure compliance and continuous improvement.
  • Support Corrective and Preventive Actions, Change Controls, internal audits, and other regulatory commitments.
  • Execute batch record sections and final review in a timely manner to meet production targets.
  • Manage +QDCI L1 boards to meet company key performance indicators and drive change; establish performance expectations and evaluate direct reports.
  • Manage employee development goals to foster growth and skill development.
  • Improve communication between employees through shift-change huddles.
  • Manage personnel attendance using the Labor Utilization Role-Based Schedule Tool, ADP, and Workday.
  • Participate in onboarding new hires to ensure smooth integration.
  • Monitor Metasys and Labwatch applications to ensure good manufacturing practice status on the production floor.
  • Serve as an escalation point and make decisions to resolve issues promptly.
  • Lead shop-floor project work and provide assistance and recommendations regarding processes or equipment.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...